Focal Health and China Resources Sanjiu Launch Innovative Real-World Study (RWS) Project at Focal Health Innovation Medical Ecosystem Partner Conference

On November 24, the “2021 Yuanxin Technology Sci-Tech Innovation Medical Ecosystem Partner Exchange Conference,” themed “Focus on Patients, Unite for Innovation,” was successfully held in Shanghai. Corporate representatives and industry experts from diverse fields—including biopharmaceuticals, healthcare institutions, insurtech, and industrial research—came together at the conference to explore how innovative technologies can better serve patients in the digital era, foster industry synergy, and build a patient-centered whole-course disease management system.

At this conference, Beijing Yuanxin Technology Group Co., Ltd. (hereinafter referred to as “Yuanxin Technology Group”) officially announced the integration of its ecological service capabilities across multiple business segments, launching the “Yuan Dongli” one-stop out-of-hospital pharmaceutical service platform. This platform provides pharmaceutical partners with a one-stop solution for rapid and effective access to out-of-hospital medications and patient services, comprehensively addressing needs in pharmaceutical distribution, innovative payment models, whole-course patient care, and innovative marketing. Built upon Yuanxin Technology Group’s comprehensive capabilities in medical consultation, medication management, and insurance services, “Yuan Dongli” collaborates with industry partners to deliver high-quality healthcare services to patients, helping them better embrace health.

Tian Jing, Deputy General Manager of the Innovation Marketing Center at Yuanxin Technology Group, released “Yuan Dongli” at the conference.

“Yuan Dongli” One-Stop Service Platform’s professional capabilities encompass four core service modules: the one-kilometer out-of-hospital patient service network, innovative payment solutions, Internet-plus whole-course patient services, and full-stack medical marketing services. These modules form a systematic, integrated service capability, providing pharmaceutical industry partners with a comprehensive one-stop solution for rapid and effective out-of-hospital drug access and patient services.

The innovative Real-World Study (RWS) project launched by Yuanxin Technology Group and China Resources Sanjiu at this conference represents a new practice of the “Yuan Power” innovative service capabilities. Tu Feina, General Manager of the Anti-Infective Division of China Resources Sanjiu, introduced the innovative RWS research conducted in collaboration with Yuanxin Technology Group at the conference. This initiative combines customized commercial insurance with RWS, enabling patients to reduce their financial burden from diseases, facilitating more effective implementation of RWS, and providing patients with more comprehensive disease management services.

Tu Feina, General Manager of the Anti-Infective Division at China Resources Sanjiu, stated, “The clinical adoption of new drugs requires enhancing the confidence of both physicians and patients, while simultaneously acquiring more real-world evidence and continuously monitoring drug safety and efficacy. Yuanxin Technology has supported RWS studies for ‘Futashu’ and provided comprehensive health protection services for patients. Its one-stop, end-to-end service capability has provided a solid guarantee for the high-quality implementation of the project.”

On-site Photos of the Official Launch of the Innovative RWS Project by Yuanxin Technology Group and China Resources Sanjiu

Luo Dongtao, Co-President of Yuanxin Technology Group, stated, “The strategic partnership between Yuanxin Technology Group and China Resources Sanjiu represents an innovative practice of our ‘Yuan Power’ one-stop solution for pharmaceutical company partners. It leverages the advantages of innovative payment models while conducting in-depth and effective real-world studies (RWS). Yuanxin Technology Group will continue to enhance and expand its out-of-hospital patient service capabilities, collaborating with numerous partners to drive innovation and build a comprehensive, end-to-end patient service system.”

Yuanxin Technology Group will leverage its end-to-end service advantages in real-world studies, its professional R&D services for pharmaceutical companies, and its Yuanxin Pharmacist whole-course disease management services to jointly promote the clinical adoption of two new drugs, including Futasu (the only lymph node tracer for thyroid cancer approved by the NMPA), thereby benefiting more patients.

The conference theme, “Focus on Patients, Unite for Innovation,” is also reflected in efforts to advance smart healthcare, with in-depth discussions centered on leveraging internet-based tools to deliver effective patient services and long-term management. Cao Lei, Chief Strategy Officer of Yuanxin Healthcare, shared the company’s Whole-Course Disease Management Platform solution. By integrating CRM principles with clinical workflows and harnessing internet and big data technologies, Yuanxin’s Whole-Course Disease Management approach is applicable to most disease types and scenarios. For more complex conditions, it provides standardized, full-cycle treatment and systematic services, offering a comprehensive disease management solution that covers all stages from prevention, diagnosis, and treatment to rehabilitation. The Yuanxin Whole-Course Disease Management Platform aims to improve patients’ healthcare experience and satisfaction, enhance medication adherence and disease awareness, and enable better treatment outcomes through end-to-end guidance.

Yuanxin Healthcare’s “Whole-Course Disease Management Platform Solution” facilitates the development of internet hospitals, breaking down the “walls” of traditional hospitals and providing patients with integrated innovative services such as online prescriptions, online follow-up consultations, and remote consultations. This makes it possible to achieve interconnectivity of medical service data and form a closed-loop system integrating online and offline medical services. Qu Feng, Director of the Remote Consultation Center at Nanjing Drum Tower Hospital’s Internet Hospital, shared on-site that Yuanxin Healthcare’s internet hospital solution has supported Drum Tower Hospital in building and operating its internet medical service platform, establishing “Internet + Healthcare” services, optimizing medical resources, promoting the flow of high-quality medical resources and tiered diagnosis and treatment, thereby delivering convenient and beneficial services to the public.

The complete ecosystem of healthcare services comprises not only the demand side (patients) and the supply side (providers), but also an indispensable third pillar: the payer. Peng Xuan, CEO of Yuanxin Huibao, shared insights on the topic of “Specialty Drugs Driving City-Specific Customized Commercial Medical Insurance.” Peng pointed out that within the existing multi-tiered social security framework, the key to the long-term and sustainable development of commercial supplemental medical insurance lies in reasonably and effectively balancing the interests of various stakeholders—including the government, consumers, insurance companies, and pharmaceutical enterprises—and establishing goals and philosophies based on shared value. Market demand for “Huimin Bao” (inclusive city-specific commercial health insurance) products is robust, driven by their advantages such as affordability, no age restrictions, and no exclusions for pre-existing conditions. Peng stated that as a deep participant and promoter of such innovative insurance products, Yuanxin Huibao actively implements the principle of “inclusiveness” through the execution of “Huimin Bao” projects. Centered on the core belief that “the essence of insurance is to return to protection,” the company provides users with more comprehensive value-added health protection services, while enabling better insurance products and medical services to benefit a broader population.

To date, Yuanxin Huibao has established organic collaborations with multiple insurance companies and local government agencies, leading and participating in customized inclusive health insurance projects in dozens of cities, including Ningbo, Nantong, Hainan, Shanxi, Anhui, Tianjin, Heilongjiang, Hebei, Fujian, and Hunan, thereby contributing to the development of a multi-tiered medical security system.

At this Innovative Medical Ecosystem Partner Conference, Yuanxin Technology showcased its comprehensive value proposition—from the launch of the “Yuan Dongli” one-stop out-of-hospital pharmaceutical service platform and the sharing of successful strategic cooperation projects, to discussions on leveraging internet-based tools in smart healthcare for effective patient services and long-term management, as well as exploring how specialty drugs can drive customized commercial health insurance. These initiatives fully reflect Yuanxin Technology’s deep thinking and practical efforts centered on patient needs across various scenarios, including medical treatment, medication, and insurance. Furthermore, the conference comprehensively demonstrated Yuanxin Technology’s end-to-end layout across its business segments, continuously delivering value to a wide range of stakeholders, including hospitals, physicians, pharmaceutical companies, and insurers.